Thanks David everyone. morning and good
commercial to newly mentioned created David is advance initiative for As the most SkinTE. the the efforts for important OCE
blocks QX regard. highlight place in for and I'd building important in that growth the it's earnings I our like our to call, in greater put in to SkinTE detail position we As progress mentioned that
five terms, large a for First outline network. in simplest like adoption stages SkinTE I'd the hospital to in
engage the early influential engage to is identify First, -- adopters. and
is evaluation positive product Second, to a facilitate experience.
the Fourth, influence is utilize to broad engaging multiple early within and by Third, technology specialties. penetration system to adopters the pricing. hospital is is gain and system hospital SkinTE fifth, approval to the for peers;
complete, are tenure steps the and months. and not first is this it I in that where We our stage begin company, the months timeline process described, finding is surprising reps approximately generating inflect. have the nine fifth top nine can the longest the XX take to that to six three Considering process with revenue revenues to to roughly
We hospital of are an penetration these in at efforts for the systems. several have excited that broad recently resulted individuals large opportunity
the These actual example in SkinTE case hospitals currently have of fifth represent now and additional describe working clinical to we and I throughout appreciate recognized the would that that we these users an bring financial are the benefit opportunities To where diligently to offers these value like networks. stage are on both adoption.
a utilized the their us impact Northeast large than be After and clinical partner SkinTE treated entire outcomes a allow hospital affiliated hospitals dozen of patients system with to with to series of felt the to in network. evaluating across more with financial compelled SkinTE, their initial
spends Excluding on $XX skin skin per we estimate wound-healing various substitutes graft year this that products. and procedures, greater a than of network million size hospital
are system-wide. aggressively patient advantage by care We physicians taking educating full new of this teams and engaging focusing opportunity their on
seven six regular across which by sales and in hospital the approved systems example Overall penetration now our in hospitals, in cases our of generating systems country systems six accelerate driven just these just are of one the XX large force adoption these and Collectively upside and mentioned. other represent I to XX we the at QX. currently following physicians. This SkinTE for a hospital paid have total been clearly including and initiatives implemented represents the opportunity significant identified has
hospitals. on candidates focus to profile have meet hiring criteria. existing our that these reps To and May hired experience care with new within modified targeted we've relationships XX First, since hospital-based we wound end, deep that physician
are education to marketing be training customer segment and Second, which improved we designed have materials, significantly sales our and specific.
earlier, effectively need has be needs customer mentioned and unique each David that specific discuss As to and to able segment we address.
that acquired identify and are us to market utilizing hospital by detailed specialty. have Third, now data physicians high-value target and by and we allows
their become David fourth, to experiences utilizing speakers earlier present has of champions a are program. physicians growing to of SkinTE product with their programs And These base a educational create mentioned bureau group peers. a allow to as what we
are my year during of the significantly We the educational can programs of throughout process half country programs in peer-to-peer second the a in these number adoption. these of experience accelerate and scheduling the
both key metrics of metrics variety specific cases; These I of increasing to the progress will performing the At paid an better like our point, performance the a SkinTE this share forward the early plan and on that give new help of towards our would metrics to revenue for metrics growth. we repeat; quarter. course shared on show help performance project insight paid physicians with adoption. total update of revenue. call number this cases future that include believes and and OCE of key number focus into going past we've the goal and Starting the In
process, the will We certainly continue sales discuss during which desired. of the Q&A track if we to other components can
QX can larger increase physician to wounds in in increasing XX be paid SkinTE. uptake cases attributed of This which revenue revenue were cases on traumatic So resulted in a versus QX, XX% performed roughly XX confidence quarter-over-quarter. an in increase based in
size. volatility stage to as this see to wound at of we relates However, expect it continued commercialization
To physician users with quarter. consistent supplement a important develop is base of it physician core and establish us we of SkinTE new believe each a for growing repeat and to revenue, strong of them users
and as who we who XX To physician has a end user compared We define a had we performed cases define users repeat QX. that new user first a nine in QX has to a paid in performed their multiple paid case. as physician repeat
in we from in users our driving in focus Additionally existing QX XX to QX. this new Reflected additional in QX. had XX these data users cases compared on was
the and SkinTE we grow this off hospitals our using the educational programs later new repeat to further penetrate in coming peer-to-peer quarters both expect considerably as month. kick currently users and We
by strong fronts progress point time and that business grow place in this commercial QX. our confident At are have made a in multiple early are encouraged QX on plan have in we the we into to and we
progress we Additionally, I'm building report made evidence. that scientific to pleased have
abstracts presented posters composed nine In five presentations. of were QX, and XX SkinTE-related podium
granted series XXX were year's podium conference. have at case of in pilot accepted awards treatment clinical the abstract the to and was a a recognitions. American Annual received honored Surgery XX Podiatry by Association a XXXX following presentation special wound as this We types The from designated late-breaking are top Plastic at top We study Today. our Society abstract in highlighting as a innovative the Diabetes use multiple Meeting. was A named American data of and DFUs SkinTE
Podiatry Finally, the a Journal. study the the in Watch Diabetes DFU in Medical column Today pilot results from featured were
of course, future drive help Of adoption component I'd highlight commercialization are our some so the reimbursement. taking to and steps of like to clinical are important initiative, trials an we
reaching conference anticipate interim trial We are in currently expect we next trials, enrolling early the two multicenter be DFU enrollment or control trials in XXXX We those reporting to year later analysis results the and their which next randomized be this completed more slowly as will is spring later historically prevalence. year. enroll VLU interim VLU lower due in expected cycle. reported to The
to of plan positive interim and feedback later our the burn regional conclude and year. Given at we this trial, a conference study head-to-head this safety profile results report
Additionally, of more we treatment will as clinical the working useful wounds enrollment, commence to ultimately are surgeons burn trial physicians We be burn gain evaluating adoption SkinTE. a to that practices. enhance investigators that prospective evidence is and their rapid our this data result in relevant with with additional large study burn more will burn, anticipate to focused produce on
regarding like team optimizing and our an SkinTE of I'd comments can focus to having is input David's react in R&D and finally, developing they OsteoTE onsite A quickly that products. providers' expand our to And benefit R&D technologies. on related on
bring KOLs we to Last year, first in-human the R&D it FDA working was the and and to hospital to where now initiate registered point use. able with OsteoTE systems the with team was the are
human expect commercial We data for partners use pursue OsteoTE. potential early this to to
we our to and bioactive technologies knowledge pipeline. of develop leverage continue Additionally, to our further regenerative
taken the extract term. prioritize pipeline the value of action to our conclude near decisive and To has in to OCE order SkinTE to in accelerate adoption the
a financial call Now, to the Paul turn for update. I'd to over Mann like